Made Scientific, Inc.

Made Scientific, Inc. is a U.S.-based contract development and manufacturing organization (CDMO) specializing in cell therapies. Headquartered in Princeton, New Jersey, the company's core mission is to accelerate life-saving cell therapies from development to commercialization by streamlining complex processes, accelerating timelines, and overcoming scientific and operational hurdles. Made Scientific operates as a private entity and is an operating subsidiary of South Korea's GC Corporation, a global leader in the pharmaceutical and biotechnology sector.

The company provides end-to-end CDMO services for autologous and allogeneic cell therapy products, covering clinical and commercial supply. Its comprehensive offerings include process and analytical development, Good Manufacturing Practice (GMP) and non-GMP manufacturing, aseptic fill & finish, quality control testing, regulatory support, and workforce development and training. Made Scientific operates two U.S.-based manufacturing facilities, including a 60,000 sq. ft. flagship GMP facility in Princeton, NJ, and a facility in Newark, NJ.

Made Scientific, led by Chairman and CEO Syed T. Husain, rebranded from BioCentriq in March 2025 to reflect its focus on Manufacturing and Development Excellence. In August 2025, the company celebrated the grand opening of its new Princeton headquarters and GMP manufacturing facility, following a $12 million investment. Further demonstrating its growth, Made Scientific announced a 12,000 sq. ft. expansion of its Princeton GMP manufacturing cleanroom space in May 2025/2026 to support late-phase and commercial cell therapy manufacturing. The company has also engaged in strategic partnerships, including collaborations with Basilard BioTech, Streamline Bio, Regenicin, and RoosterBio.